Comparative chronic ulcerogenic and anti-inflammatory effects of CT-3 and selected NSAIDs in rats
| Test Drug | ED50 (95% CL) | Therapeutic Index of ED50 for Ulcer to ED50 for Anti-inflammatory | |
|---|---|---|---|
| Ulcerogenic7-a | Anti-inflammatory7-b | ||
| mg/kg/day | |||
| CT-3 | >307-c | 0.17-c | >300 |
| Ibuprofen | 115 (97–135) | 32 (3–302) | 3.6 |
| Diclofenac | 8.3 (6.6–10) | 0.6 (0.5–0.8) | 13.8 |
| Indomethacin | 4.0 (2.9–5.5) | 0.3 (0.2–0.4) | 13.3 |
| Ketoprofen | 8.2 (6.2–11) | 0.2 (0.1–0.6) | 41.0 |
| Ketrolac | 10.2 (6.8–15) | 1.4 (0.7–3.0) | 7.3 |
Adapted from Young and Yee (1994).
↵7-a Gastrointestinal ulceration of the test drugs was determined after 5 days of chronic administration.
↵7-b The anti-inflammatory evaluation of the test drugs was performed in the rat adjuvant arthritis test.
↵7-c The ED50 values for CT-3 was only an estimate because a dosage of up to 30 mg/kg/day administered for 5 days did not produce any ulceration. In addition, the anti-inflammatory ED50dosage of CT-3 in the rat adjuvant arthritis test was estimated to be equal to 0.1 mg/kg (Zurier et al., 1998).